Vascular Dementia Pipeline

DelveInsight’s, “Vascular Dementia Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Vascular Dementia: Understanding

Vascular Dementia: Overview

Vascular Dementia is the second most common form of dementia after Alzheimer’s disease and results from impaired cerebral blood flow leading to brain damage. It is not a single disease but a spectrum of cognitive disorders caused by cerebrovascular pathology, including large vessel strokes, small vessel disease, and chronic ischemia. The condition is strongly associated with aging and vascular risk factors such as hypertension, diabetes, hyperlipidemia, and smoking. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) subsumes all dementing diseases under the syndromic term MND.

Vascular Dementia presents with variable clinical features depending on the extent and location of vascular injury in the brain. Patients commonly exhibit impaired attention, slowed thinking, and reduced executive function, while memory loss is usually less prominent in early stages compared to Alzheimer’s disease. The condition often follows a stepwise progression, with sudden worsening after cerebrovascular events such as strokes. Motor symptoms including gait instability, limb weakness, and coordination issues are frequently observed. Behavioral changes such as depression, apathy, and emotional lability are also common, significantly affecting daily functioning.

Vascular dementia results from impaired cerebral blood flow leading to ischemic or hemorrhagic brain injury and subsequent neuronal loss. The condition is primarily driven by large vessel disease causing cortical infarcts, small vessel disease leading to white matter damage, and chronic hypoperfusion resulting in diffuse brain injury. These vascular insults trigger a cascade of pathological processes including oxidative stress, inflammation, and excitotoxicity. Over time, these mechanisms disrupt neuronal connectivity and damage regions involved in cognition and behavior. The cumulative effect of repeated vascular events ultimately leads to progressive cognitive decline.

The diagnosis of vascular dementia is based on clinical evaluation supported by neuroimaging and cognitive testing. Physicians assess cognitive decline, particularly executive dysfunction and attention deficits, along with a history of cerebrovascular events. Brain imaging techniques such as MRI or CT scans play a crucial role in identifying infarcts, lacunar lesions, and white matter abnormalities. Standardized cognitive assessment tools like MMSE and MoCA are used to quantify the severity of impairment. Establishing a temporal relationship between vascular events and cognitive symptoms is essential for accurate diagnosis and differentiation from other dementias.

Management of vascular dementia focuses on preventing further vascular damage and alleviating symptoms, as no definitive cure is currently available. Controlling underlying risk factors such as hypertension, diabetes, hyperlipidemia, and smoking is the cornerstone of treatment. Pharmacological options include antiplatelet agents to reduce stroke risk and cognitive enhancers like cholinesterase inhibitors or memantine for symptom management. Non-pharmacological approaches such as cognitive rehabilitation, physical exercise, and lifestyle modifications play an important supportive role. A multidisciplinary approach is often required to improve quality of life and slow disease progression.

"Vascular Dementia Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Dementia pipeline landscape is provided which includes the disease overview and Vascular Dementia treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Dementia.

Vascular Dementia Emerging Drugs Chapters

This segment of the Vascular Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Dementia Emerging Drugs

Apabetalone: Resverlogix Corporation

Apabetalone is the world leader in a new class of drugs designed to regulate disease-associated proteins. Traditional therapeutics target a single, disease-causing factor with the intention of treating or curing complex and chronic illnesses. By inhibiting the action of bromodomain and extraterminal domain (BET) proteins, apabetalone positively affects multiple disease-causing biological processes, leading to a new paradigm shift in the treatment of chronic disease. Apabetalone has a unique mechanism of action, working at the level of “transcription”. As a selective inhibitor of the BET family of proteins, apabetalone has the ability to normalize dysregulated epigenetics that lie at the heart of many chronic diseases. Apabetalone blocks the action of BET proteins, bringing the increased production of dysregulated proteins back down to healthier levels. Apabetalone can be administered as a twice-daily tablet. Most importantly, apabetalone has proven to be safe. Due to its unique epigenetic mechanism, the company continues to discover more ways that apabetalone can benefit patients across a broader range of chronic diseases, including neurodegenerative diseases, peripheral artery disease, and a number of rare diseases. Currently, the drug is in the Phase III stage of its development for the treatment of VaD.

ACP-01: Hemostemix

ACP 01 is an autologous stem cell–based therapy developed by Hemostemix that involves harvesting angiogenic cell precursors from a patient’s own peripheral blood, expanding these cells in culture, and then reinjecting them to promote angiogenesis and microvascular repair. The therapy is being studied as an intrathecal injection into the cerebrospinal fluid, with the goal of improving cerebral perfusion, up regulating neurotrophic factors and chemokines, and stabilizing or enhancing cognitive function. Currently, the drug is in the Phase I stage of its development for the treatment of Vascular Dementia.

Further product details are provided in the report...

Vascular Dementia: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Dementia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vascular Dementia

There are approx. 8+ key companies which are developing the therapies for Vascular Dementia. The companies which have their Vascular Dementia drug candidates in the most advanced stage, i.e. Phase III include, Resverlogix Corporation

Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

Vascular Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Dementia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Vascular Dementia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Dementia drugs.

Vascular Dementia Report Insights

Vascular Dementia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Vascular Dementia Report Assessment

Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Vascular Dementia drugs?
How many Vascular Dementia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Dementia?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Dementia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Vascular Dementia and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players